Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Identifying stroke therapeutics from preclinical models: a network meta-analysis
EF 2021-22
Résumé
Stroke is the second leading cause of death worldwide and the third-leading cause of death and disability combined, with more than six and a half million deaths and 143 million experiencing new permanent disability annually. There are limited interventions to treat stroke, which few patients are eligible to receive. Given the burden of stroke, and the limitation in scope of who can receive treatment and limited efficacy for those that do, a multitude of therapies are being tested preclinically in animal models. However, it is difficult to identify the most promising therapeutic candidates for translation from animal to human studies due to the lack of efficacy comparison of all treatment options. To address this issue, a network meta-analysis (NMA) can be beneficial since this method compares multiple therapies directly and indirectly in a single analysis. This means that even if two therapies have never been directly compared in an experiment, the NMA can estimate how each would fare based on indirect comparisons. I will use the NMA to evaluate a large number of tested preclinical stroke therapeutics. In addition, I will systematically search databases to identify preclinical animal stroke experiments that tested the efficacy of therapies in combination with the gold-standard therapy, alteplase, compared to alteplase alone. The primary outcome of interest is infarct volume, which is related to the severity of disability following stroke. Multiple stakeholders will aid in the final stages of the review to help with interpretation and dissemination of the review findings. An NMAs unique ability to compare multiple interventions at a time has great potential to identify therapies that hold the greatest promise for further research development.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
467208
Name
Sharif Ayni
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying stroke therapeutics from preclinical models: a network meta-analysis
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Network Meta-Analysis; Preclinical; Stroke; Systematic Review; Translation
Abstract
Stroke is the second leading cause of death worldwide and the third-leading cause of death and disability combined, with more than six and a half million deaths and 143 million experiencing new permanent disability annually. There are limited interventions to treat stroke, which few patients are eligible to receive. Given the burden of stroke, and the limitation in scope of who can receive treatment and limited efficacy for those that do, a multitude of therapies are being tested preclinically in animal models. However, it is difficult to identify the most promising therapeutic candidates for translation from animal to human studies due to the lack of efficacy comparison of all treatment options. To address this issue, a network meta-analysis (NMA) can be beneficial since this method compares multiple therapies directly and indirectly in a single analysis. This means that even if two therapies have never been directly compared in an experiment, the NMA can estimate how each would fare based on indirect comparisons. I will use the NMA to evaluate a large number of tested preclinical stroke therapeutics. In addition, I will systematically search databases to identify preclinical animal stroke experiments that tested the efficacy of therapies in combination with the gold-standard therapy, alteplase, compared to alteplase alone. The primary outcome of interest is infarct volume, which is related to the severity of disability following stroke. Multiple stakeholders will aid in the final stages of the review to help with interpretation and dissemination of the review findings. An NMAs unique ability to compare multiple interventions at a time has great potential to identify therapies that hold the greatest promise for further research development.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sharif, Ayni
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~